{
    "clinical_study": {
        "@rank": "166365", 
        "arm_group": [
            {
                "arm_group_label": "ISIS TTR Rx", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of ISIS TTR Rx given for 65\n      weeks in patients with Familial Amyloid Polyneuropathy"
        }, 
        "brief_title": "Efficacy and Safety of ISIS-TTRRx in Familial Amyloid Polyneuropathy", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Familial Amyloid Polyneuropathy", 
        "condition_browse": {
            "mesh_term": [
                "Polyneuropathies", 
                "Amyloid Neuropathies, Familial", 
                "Amyloid Neuropathies"
            ]
        }, 
        "detailed_description": {
            "textblock": "Familial Amyloid Polyneuropathy (FAP) is a rare, hereditary disease caused by mutations in\n      the transthyretin (TTR) protein.  TTR is made by the liver and secreted into the blood.  TTR\n      mutations cause it to misfold and deposit in multiple organs causing FAP.\n\n      ISIS TTR Rx is an antisense drug that decreases the amount of mutant and normal TTR made by\n      the liver.  It is predicted that decreasing the amount of TTR protein will result in a\n      decrease in the formation of TTR deposits, and thus slow or stop disease progression.\n\n      The purpose of this study is to determine if ISIS TTR Rx can slow or stop the nerve damage\n      caused by TTR deposits.  This study will enroll late Stage 1 and early Stage 2 FAP patients.\n       Patients will receive either ISIS TTR Rx or placebo for 65 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Stage 1 and Stage 2 FAP patients with the following:\n\n               1. NIS score >15 and <85\n\n               2. Ability to walk unaided or with the use of no more than one stick/cane\n\n               3. Documented transthyretin variant by genotyping\n\n               4. Documented amyloid deposit by biopsy\n\n          -  Females of child-bearing potential must use appropriate contraception and must be\n             non-pregnant and non-lactating. Males engaged in relations of child-bearing potential\n             must use appropriate contraception\n\n        Exclusion Criteria:\n\n          -  Low Retinol level at screen\n\n          -  Karnofsky performance status \u226450\n\n          -  Poor Renal function\n\n          -  Known type 1 or type 2 diabetes mellitus\n\n          -  Other causes of sensorimotor or autonomic neuropathy (e.g., autoimmune disease)\n\n          -  If previously treated with Vyndaqel\u00ae, must have discontinued treatment for 2 weeks\n             prior to Study Day 1. If previously treated with Diflunisal, must have discontinued\n             treatment for 3 days prior to Study Day 1\n\n          -  Previous treatment with any oligonucleotide or siRNA within 12 months of screening\n\n          -  Prior liver transplant or anticipated liver transplant within 1 yr of screening\n\n          -  New York Heart Association (NYHA) functional classification of \u22653\n\n          -  Acute Coronary Syndrome or major surgery within 3 months of screening\n\n          -  Known Primary or Leptomeningeal Amyloidosis\n\n          -  Anticipated survival less than 2 years\n\n          -  Have any other conditions in the opinion of the investigator which could interfere\n             with the patient participating in or completing the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "195", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01737398", 
            "org_study_id": "ISIS 420915-CS2"
        }, 
        "intervention": [
            {
                "arm_group_label": "ISIS TTR Rx", 
                "description": "300 mg ISIS TTR Rx administered subcutaneously 3 times on alternate days in the first week and then once-weekly for 64 weeks.", 
                "intervention_name": "ISIS TTR Rx", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo administered subcutaneously 3 times on alternate days in the first week and then once-weekly for 64 weeks.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "FAP", 
            "Familial Amyloid Polyneuropathy"
        ], 
        "lastchanged_date": "December 2, 2013", 
        "location": [
            {
                "contact": {
                    "email": "vero@uci.edu", 
                    "last_name": "Veronica Martin", 
                    "phone": "714-456-7760"
                }, 
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92868"
                    }, 
                    "name": "University of California, Irvine"
                }, 
                "investigator": {
                    "last_name": "Annabel Wang, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mdbenson@iupui.edu", 
                    "last_name": "Merrill Benson, MD", 
                    "phone": "317-278-3426"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Merrill Benson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kburks1@jhmi.edu", 
                    "last_name": "Kathy Burks", 
                    "phone": "410-502-6006"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21205"
                    }, 
                    "name": "Johns Hopkins University Bayview Medical Center"
                }, 
                "investigator": {
                    "last_name": "Michael Polydefkis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Samantha.Pappin@bmc.org", 
                    "last_name": "Samantha Pappin", 
                    "phone": "617-638-4494"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02118"
                    }, 
                    "name": "Boston University School of Medicine - Amyloid Treatment & Research Program"
                }, 
                "investigator": {
                    "last_name": "John Berk, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Gertz.morie@mayo.edu", 
                    "last_name": "Morie Gertz, MD", 
                    "phone": "507-284-2511"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "investigator": {
                    "last_name": "Morie Gertz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tb2325@cumc.columbia.edu", 
                    "last_name": "Thomas Brannagan", 
                    "phone": "212-305-0405"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia University Medical Center - The Neurological Institute"
                }, 
                "investigator": {
                    "last_name": "Thomas Brannagan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ghimja.berhanu@mssm.edu", 
                    "last_name": "Ghimja Berhanu", 
                    "phone": "212-241-1617"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10029"
                    }, 
                    "name": "Mount Sinai Medical Center"
                }, 
                "investigator": {
                    "last_name": "Peter Gorevic, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "vplante@free.fr", 
                    "last_name": "Prof Plante", 
                    "phone": "+33 6 62 32 83 91"
                }, 
                "facility": {
                    "address": {
                        "city": "Creteil", 
                        "country": "France", 
                        "zip": "94000"
                    }, 
                    "name": "CHU Henri Mondor - Department of Neurology"
                }, 
                "investigator": {
                    "last_name": "Violaine Plante-Bordeneuve, MD, Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "david.adams@bct.aphp.fr", 
                    "last_name": "Prof David Adams", 
                    "phone": "+33 1 45 21 27 11"
                }, 
                "facility": {
                    "address": {
                        "city": "Le Kremlin Bicetre", 
                        "country": "France", 
                        "zip": "94275"
                    }, 
                    "name": "CHU Bicetre Aphp French Referral Center for FAP/Cornamyl Network"
                }, 
                "investigator": {
                    "last_name": "David Adams, MD, Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "hepar@ukmuenster.de", 
                    "last_name": "Hartmut Schmidt, Prof.", 
                    "phone": "+49 251 83 57935"
                }, 
                "facility": {
                    "address": {
                        "city": "Munster", 
                        "country": "Germany", 
                        "zip": "48149"
                    }, 
                    "name": "UKM; Universit\u00e4tsklinikum M\u00fcnster, Klinik f\u00fcr Transplantationsmedizin"
                }, 
                "investigator": {
                    "last_name": "Hartmut Schmidt, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "gmerlini@unipv.it", 
                    "last_name": "Giampaolo Merlini, Prof.", 
                    "phone": "+39(0)382-502994"
                }, 
                "facility": {
                    "address": {
                        "city": "Pavia", 
                        "country": "Italy", 
                        "zip": "27100"
                    }, 
                    "name": "Centro per lo Studio e la Cura delle Amiloidosi Sistemiche - Fondazione IRCCS Policlinico San Matteo"
                }, 
                "investigator": {
                    "last_name": "Giampaolo Merlini, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "imsconceicao@gmail.com", 
                    "last_name": "Dra. Conceicao", 
                    "phone": "+351 217 930 629"
                }, 
                "facility": {
                    "address": {
                        "city": "Lisbon", 
                        "country": "Portugal", 
                        "zip": "1649-035"
                    }, 
                    "name": "CHLN - Hospital de Santa Maria"
                }, 
                "investigator": {
                    "last_name": "Isabel Conceicao, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tcoelho@netcabo.pt", 
                    "last_name": "Dra. Teresa Coelho", 
                    "phone": "+351 226 068 114"
                }, 
                "facility": {
                    "address": {
                        "city": "Porto", 
                        "country": "Portugal", 
                        "zip": "4099-001"
                    }, 
                    "name": "CHP-HGSA, Unidade Clinica de Paramiloidose"
                }, 
                "investigator": {
                    "last_name": "Teresa Coelho, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "t.lane@ucl.ac.uk", 
                    "last_name": "Thirusha Lane", 
                    "phone": "020 7433 2759"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "NW3 2PF"
                    }, 
                    "name": "University College London - National Amyloidosis Centre"
                }, 
                "investigator": {
                    "last_name": "Carol Whelan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France", 
                "Germany", 
                "Italy", 
                "Portugal", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy", 
        "overall_contact": {
            "email": "patients@isisph.com", 
            "last_name": "Isis Pharmaceuticals", 
            "phone": "800-679-4747"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "France: Ministry of Health", 
                "Portugal: National Pharmacy and Medicines Institute"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Efficacy of ISIS TTR Rx as measured by change from baseline in the modified Neuropathy Impairment Score +7", 
                "safety_issue": "No", 
                "time_frame": "65 weeks"
            }, 
            {
                "measure": "Efficacy of ISIS TTR Rx as measured by change from baseline in the Norfolk Quality of Life Diabetic Neuropathy questionnaire", 
                "safety_issue": "No", 
                "time_frame": "65 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01737398"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Modified Body Mass Index and Body Mass Index\nIndividual components of the mNIS+7\nNIS+7", 
                "measure": "Efficacy of ISIS TTR Rx based on the change from baseline in the following measures:", 
                "safety_issue": "No", 
                "time_frame": "65 weeks"
            }, 
            {
                "measure": "Pharmacodynamic effect of ISIS TTR Rx based on the change from baseline in transthyretin and retinol binding protein 4", 
                "safety_issue": "No", 
                "time_frame": "65 weeks"
            }
        ], 
        "source": "Isis Pharmaceuticals", 
        "sponsors": {
            "collaborator": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Isis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}